| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
1 UMR 7034, CNRS, Universite Louis Pasteur, Illkirch, France
2 Department of Molecular Pharmacology and Biological Chemistry, Northwestern University, Chicago, USA
3 UMR 7081, CNRS, Universite Louis Pasteur, Illkirch, France
* To whom correspondence should be addressed. E-mail: nain{at}aspirine.u-strasbg.fr.
Myosin light chain kinase (MLCK) plays a key role in the regulation of actomyosin contraction in a large variety of cells. Two isoforms have been described: a short isoform (MLCK108), widely expressed in smooth muscle cells; and a long isoform (MLCK210), mainly localized in the endothelium. This study investigated the consequences on different cardiovascular parameters of MLCK210 gene deletion using MLCK210 knock out (KO) mice and of pharmacological inhibition of the kinase using a specific MLCK inhibitor. Deletion of MLCK210 did not affect systolic blood pressure and heart rate or echocardiographic measurements. Electrocardiographic analysis showed neither atrio- nor intra-ventricular conduction or repolarization defects. Ex-vivo responses of aortic rings to vasoconstrictor and vasodilator agonists were not modified in MLCK210 null mice. However, deletion of MLCK210 attenuated shear-stress induced dilation and produced changes in the balance of endothelial relaxing factors of small mesenteric arteries (SMA). In particular, a reduced flow-mediated NO-dependent dilation was observed. However, it was partially compensated by enhanced indomethacin-sensitive dilation. No significant changes were detected in the endothelium-derived hyperpolarizing-component of the vasodilator response. The above effects of MLCK210 gene deletion were confirmed in SMA from WT mice, by the use of the MLCK enzymatic inhibitor, MMZ-10-057. In summary, deletion of MLCK210 was not associated with abnormalities of main in-vivo cardiovascular parameters in mice. This study demonstrates a role for MLCK210 in the regulation of flow-dependent dilation in SMA.
This article has been cited by other articles:
|
|
 |
|
  Y. Ishikawa and R. Kurotani Cardiac Myosin Light Chain Kinase: A New Player in the Regulation of Myosin Light Chain in the Heart Circ. Res., March 14, 2008; 102(5): 516 - 518. [Full Text] [PDF]
|
|
|
|
|
|
J. Y. Chan, M. Takeda, L. E. Briggs, M. L. Graham, J. T. Lu, N. Horikoshi, E. O. Weinberg, H. Aoki, N. Sato, K. R. Chien, et al. Identification of Cardiac-Specific Myosin Light Chain Kinase Circ. Res., March 14, 2008; 102(5): 571 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tesse, G. Al-Massarani, R. Wangensteen, S. Reitenbach, M. C. Martinez, and R. Andriantsitohaina Rosiglitazone, a Peroxisome Proliferator-Activated Receptor-{gamma} Agonist, Prevents Microparticle-Induced Vascular Hyporeactivity through the Regulation of Proinflammatory Proteins J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 539 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. P. Herring, O. El-Mounayri, P. J. Gallagher, F. Yin, and J. Zhou Regulation of myosin light chain kinase and telokin expression in smooth muscle tissues Am J Physiol Cell Physiol, November 1, 2006; 291(5): C817 - C827. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
